Table 2.
Comparison of baseline data between the low-and high-risk groups.
| Low-risk group (N = 37) | High-risk group (N = 19) | P | |
|---|---|---|---|
| Sex (N [%]) | 0.008 | ||
| Women | 25 (67.6%) | 5 (26.3%) | |
| Men | 12 (32.4%) | 14 (73.7%) | |
| Age/Yr (Mean ± SD) | 47.59 ± 11.06 | 55.63 ± 9.44 | 0.009 |
| Course/Yr (Median [P25, P75]) | 2.00 (1.00,4.00) | 4.00 (2.50,6.50) | 0.024 |
| Follow-up/Yr (Median [P25, P75]) | 6.55 (5.47,7.48) | 6.94 (5.80,8.30) | 0.416 |
| Subtype of MD (N [%]) | 1.000 | ||
| Classical MD | 30 (81.1%) | 16 (84.2%) | |
| Non-classical MD | 7 (18.9%) | 3 (15.8%) | |
| Glycerol test (N [%]) | |||
| Positive | 14 (37.8%) | 9 (47.4%) | 0.689 |
| Negative | 23 (62.2%) | 10 (52.6%) | |
| PTA (Mean ± SD) | 50.32 ± 17.62 | 54.68 ± 14.82 | 0.360 |
| Hearing stage (N [%]) | 0.378 | ||
| I | 4 (10.8%) | 1 (5.3%) | |
| II | 7 (18.9%) | 1 (5.3%) | |
| III | 23 (62.2%) | 16 (84.2%) | |
| IV | 3 (8.1%) | 1 (5.3%) | |
| Type of audiogram (N [%]) | 0.794 | ||
| Ascending | 9 (24.3%) | 6 (31.6%) | |
| Non-ascending | 28 (75.7%) | 13 (68.4%) | |
| Frequency (Median [P25, P75]) | 6.00 (2.00,12.00) | 4.00 (1.50,10.50) | 0.855 |
| Dysfunction score (N [%]) | 28 | 15 | 0.923 |
| 2 | 9 (32.1%) | 4 (26.7%) | |
| 3 | 14 (50%) | 8 (53.3%) | |
| 4 | 3 (10.7%) | 2 (13.3%) | |
| 5 | 1 (3.6%) | 1 (6.7%) | |
| 6 | 1 (3.6%) | 0 (0%) | |
| Medication (N [%]) | 29 (85.29%) | 17 (94.44%) | 0.599 |
| Betahistine | 23 (67.65%) | 17 (94.44%) | 0.066 |
| Diuretic | 11 (32.35%) | 6 (33.33%) | 0.943 |
| Hormone | 11 (32.35%) | 5 (27.78%) | 0.734 |
N, number. Yr, year. SD, standard deviation. Age, age at operation. Course, Course of Meniere’s disease. MD, Meniere’s disease. PTA, pure tone average of 0.5, 1, and 2 kHz. Frequency: the number of monthly vertigo attacks during the 6 months before the operation. Medication: the use of betahistine, diuretic, or hormone after the operation.